Healthcare Technology and Innovation

Area coordinators:

• Damián García Olmo
  damian.garcia@quironsalud.es
  Consulta su CV

foto1 tecno

Transversal strategic area composed of three consolidated groups and five associated groups, created primarily for the application of new health technologies for diagnosis and the application of innovative treatments.

Its objectives include:

• Ophthalmology Innovation Group: Develop big data systems in ocular pathologies. Develop a cell therapy trial in ocular inflammatory pathology. Search for biomarkers for uveitis.
• Medical Engineering Research and Development Group: consolidate the clinical evaluation of new devices.
• New Therapies Research Group: Study of the ADSC secretome. Study of metSEPTIN 9 in rectal cancer. Clinical trial of cell therapy in patients with Crohn's disease. Development of a system for the treatment of intraluminal tumours.
• Preclinical toxicity assay of peritoneal collagenase.
• Medical and Surgical Innovation Group: Potential association of inciso-molar hypomineralisation with other congenital anomalies of the teeth.
• Preventive Medicine-Public Health and Primary Care Group: development of epidemiological studies of both chronic and communicable diseases; study of the impact of vaccination on communicable diseases.
• Advanced Therapies Group: Development of innovative therapies for pathologies with poor prognosis. In gene therapy for the treatment of hereditary diseases, development of new treatments. Preclinical gene therapy studies on a therapeutic strategy based on genomic editing. Develop a clinical trial with genetically modified mesenchymal cells for the treatment of graft-versus-host disease in the field of regenerative medicine based on stem cell therapies.
• Regenerative Medicine and Tissue Bioengineering Group: Development of tissue engineering models for treating epithelial lesions and their biotechnological applications. In vivo correction through gene editing with adenoviral vectors for recessive dystrophic epidermolysis bullosa. CT: MSCs for chronic wound treatment (EudraCT 2019-004637-16). Microfluidic system for skin-on-a-chip applications. New gene editing tools for Epidermolysis bullosa and other types of genodermatosis. Cell therapy with MSCs for epidermolysis bullosa. Aptamer-based drug therapy for epidermolysis bullosa and chronic ulcers. Characterisation of new fibrosis modulators and therapies in recessive dystrophic epidermolysis bullosa.
• Manufacture of Advanced Therapy Medicines (Bioengineered Epithelia), according to the Cell Manufacturing Process from A to D.
• Preclinical development of a gene-editing ATMP for Epidermolysis bullosa.
• UAM Nursing Group: Extracorporeal Circulation and Perfusion: comprehensive training of students and their preparation for the competent professional performance of advanced clinical practice and research in extracorporeal circulation and perfusion, in all its areas of application, improving, with such advanced practical knowledge, the quality of care and safety that we provide to patients susceptible to these techniques.

In 2023, the change to the IIS-FJD’s Areas and Groups Structure was approved. Thus, as of 2024, the Preventive Medicine-Public Health and Primary Care group will become part of the Genetics and Genomics Area, which will be renamed Genomics and Epidemiology.

This change was approved by the Research Committee and the External Scientific Committee of the IIS-FJD.

Other changes in the group composition of the areas will be addressed during 2024.

Therapeutic effect of adipose-derived mesenchymal stem cells in a porcine model of abdominal sepsis.

Vélez-Pinto JF, Garcia-Arranz M, García-Bernal D, García Gómez-Heras S, Villarejo-Campos P, García-Hernández AM, Vega-Clemente L, Jiménez-Galanes S, Guadalajara H, Moraleda JM, García-Olmo D.

Stem Cell Res Ther. 2023 Dec 12.14(1):365.

PMID: 38087374

FI: 7,5

A human genome editing-based MLL::AF4 B-cell ALL model recapitulates key cellular and molecular leukemogenic features.

Bueno C, Torres-Ruíz R, Velasco-Hernandez T, Molina O, Petazzi P, Martinez-Moreno A, Rodríguez-Cortez VC, Vinyoles M, Cantilena S, Williams O, Vega-García N, Rodriguez-Perales S, Segovia JC, Quintana-Bustamante O, Roy A, Meyer C, Marschalek R, Smith A, Milne TA, Fraga MF, Tejedor JRR, Menendez P.

Blood. 2023 Sep 26.

PMID: 37756522

FI: 20,3

Gluten-sensitive Enteropathy in Recessive Dystrophic Epidermolysis Bullosa.

Sacedón R, de Arriba MC, Martínez-Santamaría L, Maseda R, Herráiz-Gil S, Jiménez E, Rosales I, Quintana L, Illera N, García M, Butta N, Fernández-Bello I, Lwin SM, Fernández-Arquero M, León C, McGrath JA, Vicente MÁ, Del Río M, de Lucas R, Sánchez-Ramón S, Escámez MJ.

Br J Dermatol. 2023 Sep 01.

PMID: 37655918

FI: 10,3

Is current UK transparency on clinical trials enough?

Dal-Ré R.

BMJ. 2023 Aug 22.382:1933.

PMID: 37607740

FI: 107,7

Spanish Society of Medical Radiology Journal Club: History, analysis and perspectives after ten years of experience.

Herrán de la Gala D, Biosca Calabuig C, Miranda Bautista J.

Radiologia (Engl Ed). 2023.65(4):376-384.

PMID: 37516490

FI: 19,7

Gender Perspective in the Health Technology and Innovation Area

The Health Technology and Innovation Area is made up of a group of professionals committed to respect and equality among its team members, which seeks to promote the professional development of all its personnel without discrimination based on gender or age.

6.6.0-ÁREA TECNOLOGÍA-B-GÉNERO

Health Technology and Innovation Area Future Goals

• Develop big data systems in ocular pathologies to help improve diagnosis and generate new therapies.
• Develop a cell therapy trial in ocular inflammatory pathology.
• Search for biomarkers for uveitis.
• Develop a wound healing model on rats and treatment with ADSC secretome.
• Study/characterisation of the ADSC secretome.
• Validation of metSEPTIN 9 in pancreatic tumours.
• Clinical trial with ADSC for the treatment of urinary incontinence.
• Clinical trial with collagenase as a co-adjuvant to HIPEC.
• Conclusion of the follow-up of phase I/II gene therapy clinical trials in Fanconi A anaemia and LAD-I.
• Initiation of a phase II gene therapy clinical trial in erythrocyte pyruvate kinase deficiency.
• Development of preclinical gene therapy studies for new hereditary diseases.
• Start of phase I/II clinical trial with CART cells using non-viral vectors.
• IMPD preparation for new clinical trial with genetically-modified mesenchymal stromal cells.
• Reinforcement of the porcine model in learning cervical surgical techniques to develop surgical skills in the head and neck area.
• Implementation of a cadaver model for learning the sialendoscopy technique.
• Improved surgical skills in head and neck surgery for ENT residents by working with a live animal (porcine) surgical simulation model.
• Enhancers in readthrough activity of nonsense mutations in genes causing rare skin diseases.
• New aptamer-based therapies for treating alopecia.
• CT: MSCs for chronic wound treatment (EudraCT 2019-004637-16).
• Regulatory phase EC ex vivo gene editing therapy for epidermolysis bullosa.
• Gene editing therapy for rare, dominantly inherited skin diseases.

Research Groups

• Innovation in Ophthalmology.
• Development and Innovation in Medical Engineering.
• Research in New Therapies.

• Medical and Surgical Innovation Associated Group.

• Preventive Medicine-Public Health and Primary Care Associated Group.
• Advanced Therapies (CIEMAT) Associated Group.
• Regenerative Medicine and Tissue Bioengineering (CIEMAT-UC3M) Associated Group.
• UAM Nursing Associated Group: Extracorporeal Circulation and Perfusion